Pfizer Discloses $236M in Equity Holdings via 13F Filing
PFIZER INC
Subscribe to track PFE
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Pfizer Discloses $236M in Equity Holdings via 13F Filing
Company: PFIZER INC (PFE) Form: 13F-HR | Filed: 2026/02/12 Significance: Low
Filer: Pfizer Inc. (as Institutional Manager)
Report Details: • Type: Quarterly Holdings Report • Total Holdings Value: $236,464,562 • Number of Holdings: 21 • Report Date: 12/31/2025
Key Insight: Pfizer's 13F filing reveals its portfolio of strategic equity investments, primarily in the biotech sector. The total value is immaterial (~0.15%) relative to Pfizer's $154.76B market cap.
Top Holdings by Value: • ORIC Pharmaceuticals ($44.0M) • Arvinas Inc. ($41.0M) • Celcuity Inc. ($34.8M)
Comprehensive Analysis
SEC Filing Analysis: PFIZER INC (PFE)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Pfizer reported $236.5 million in equity holdings, primarily strategic investments in biotech firms, representing a negligible fraction (0.15%) of its market capitalization.
- Market Impact: Neutral for Pfizer (PFE). The filing is informational and not indicative of a change in Pfizer's core business or financial standing.
Filer Information
| Field | Value |
|---|---|
| Company | PFIZER INC |
| Ticker Symbol | PFE (Inferred for context) |
| CIK | 0000078003 |
| Industry | Pharmaceutical Preparations |
Holdings Summary
| Field | Value |
|---|---|
| Form Type | 13F-HR |
| Period of Report | 2025-12-31 |
| Total Holdings Value | $236,464,562 |
| Number of Positions | 21 |
Financial Impact Assessment
Holdings Materiality
| Metric | Value |
|---|---|
| Total Holdings Value | $236,464,562 |
| % of Market Cap | 0.15% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The $236.5 million portfolio is insignificant when compared to Pfizer's massive $154.76 billion market capitalization. These investments do not materially affect Pfizer's financial results or overall valuation.
- Strategic Insight: The holdings provide a window into Pfizer's strategic interests, particularly in oncology and biotechnology, through its corporate venture activities. The investments are in companies like ORIC Pharmaceuticals, Arvinas, and Allogene Therapeutics.
Market Impact Analysis
- Direction: Neutral
- Reasoning: A 13F-HR is a routine, backward-looking disclosure of holdings. The value is immaterial to Pfizer's core business, and therefore, the filing is not expected to have any impact on Pfizer's stock price.
- Sentiment Indicator: Neutral
Key Takeaways
- Pfizer holds a $236.5M portfolio of strategic investments in other public companies as of December 31, 2025.
- The portfolio is heavily concentrated in the biotechnology sector, indicating areas of scientific and strategic interest for the pharmaceutical giant.
- The size of this investment portfolio is immaterial to Pfizer's overall financial position, representing only 0.15% of its market capitalization.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.